ClinicalTrials.gg
CompletedNCT01565083VELVETUpdated Nov 22, 2016Results posted

A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

A Phase 2 interventional study of Pertuzumab and Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 80 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
35th of 104
213 · median 100
Started
2012
with 2 others
Phase 2
59 of 104
17 open now
Registered
13th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 35th largest by enrollment, is one of 3 that started in 2012, is one of 59 in phase 2, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This two-cohort, open-label, multicenter, phase 2 study will assess the safety and efficacy of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line participants with metastatic or locally advanced HER2-positive breast cancer. Participants will receive pertuzumab and trastuzumab administered sequentially as separate intravenous (IV) infusions (followed by vinorelbine) and conventional sequential administration of pertuzumab and trastuzumab in separate infusion bags, followed by vinorelbine.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed and documented adenocarcinoma of the breast with or locally advanced disease not amenable to curative resection
  • -positive as assessed by local laboratory on primary or metastatic tumor
  • At least one and/or non-measurable disease evaluable according to v1.1 criteria
  • (ECOG) performance status 0 or 1
  • (LVEF) of at least 55%
  • of at least 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anti-cancer therapy in the or locally advanced breast cancer setting
  • Previous approved or investigative anti- agents in any breast cancer treatment setting, except trastuzumab and/or lapatinib in the or neoadjuvant setting
  • Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
  • Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrent disease of less than 6 months
  • History of persistent Grade 2 or higher (National Cancer Institute Common Terminology Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
  • Radiographic evidence of central nervous system metastases that are not well controlled with local therapy (irradiation or surgery)
  • Current peripheral neuropathy of NCI-CTC, version 4.0 Grade 3 or greater
  • History of other within the last 5 years, except for carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, or cancers with a similar curative outcome as those mentioned above
  • Serious uncontrolled concomitant disease that would contraindicate the use of any of the drugs used in this study or would put the participants at high risk for treatment-related complications
  • Inadequate hematologic, liver, or renal function
  • Uncontrolled hypertension or cardiovascular disease
  • , , or (HIV) infection
  • Current chronic daily treatment with (>/= 10 mg/day methylprednisolone or equivalent), excluding inhaled steroids
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion

    Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m\^2) followed by 30-35 mg/m\^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Vinorelbine

  • Experimental
    Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion

    Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Vinorelbine

Interventions

  • Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.

    Also known as: Perjeta

  • Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.

    Also known as: Herceptin

  • A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Tumor response was assessed by investigator according to RECIST v1.1. BOR was defined as percentage of participants with a confirmed complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total or pathological nodes (with short axis \[SA\] of at least (\>/=) 15 millimeter \[mm\]) were identified as target lesions (TLs) and measured and recorded at baseline. A sum of diameters (longest for non-nodal lesions, SA for nodal lesions) for all TLs was calculated and reported as baseline sum of diameters (SD). All other lesions (or sites of disease) were identified as non-TLs. CR: disappearance of all TLs and SA reduction to less than (\<) 10 mm for nodal TLs/ non-TLs. PR: \>/=30 percent (%) decrease in SD of TLs, taking as reference baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. The 95% confidence interval (CI) was computed using Clopper-Pearson approach.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

Secondary outcomes

  1. Time to Response as Assessed by Investigator According to RECIST v 1.1

    For participants with a BOR of CR or PR, time to response = (Date of first confirmed CR/PR - Date of first study treatment) + 1. For participants without a CR or PR, time to response = (Date of adequate last tumor assessment - Date of first study treatment) + 1. For participant with no tumor assessment (or if all assessments were progressive disease \[PD\]) the censoring day was set to date of first study treatment +1. CR: the disappearance of all TLs and SA reduction to \<10 mm for nodal TLs/ non-TLs. PR: \>/=30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. The 95% CI was computed using log-log transformation.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  2. Duration of Response (DOR) as Assessed by Investigator According to RECIST v 1.1

    DOR, in participants with a BOR of CR or PR, was defined as the period from the date of initial PR or CR until the date of PD or death from any cause. Participants with no documented PD or death after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively (regardless of the response at intermediate assessments). CR: the disappearance of all TLs and SA reduction to \<10 mm for nodal TLs/ non-TLs. PR: \>/=30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. The 95% CI was computed using log-log transformation.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  3. Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1 or Death From Any Cause

    PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Percentage of participants with radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or death due to any cause was reported.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  4. Progression-free Survival (PFS) as Assessed by Investigator According to RECIST v 1.1

    PFS was defined as the time from first intake of any study medication until the first radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or death due to any cause, whichever occurred first. Participants with no PFS events were censored at the time of the last evaluable tumor assessment. Participants with no baseline or no tumor assessment after the baseline visit were censored on the date of first study treatment. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Participants who had radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or died due to any cause were considered as having an event. The median PFS was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  5. Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1

    PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Percentage of participants with radio-graphically documented PD as assessed by investigator according to RECIST v1.1 was reported.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  6. Time to Progression (TTP) as Assessed by Investigator According to RECIST v 1.1

    TTP was defined as the time from first intake of any study medication until the first radio-graphically documented PD as assessed by investigator according to RECIST v1.1. Participants who did not have a radio-graphically documented PD and had died due to reason other than PD were censored on the last available tumor assessment prior to the death date. Participants with no baseline or no tumor assessment after the baseline visit were censored on the date of first study treatment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Participants who had radio-graphically documented PD as assessed by investigator according to RECIST v1.1 were considered as having an event. The median TTP was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

    Time frame: Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)

  7. Percentage of Participants Who Died From Any Cause

    Percentage of participants who died due to any cause was reported.

    Time frame: Baseline until death (up to approximately 3.5 years)

  8. Overall Survival (OS)

    OS was defined as the time from first intake of any study medication to the date of death, regardless of the cause of death. Participants who were known to be alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study treatment, and participants with no post-baseline information were censored at the date of first study treatment plus 1 day. Participants who died due to any cause were considered as having an event. The median OS was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

    Time frame: Baseline until death (up to approximately 3.5 years)

  9. Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Visual Analogue Scale (VAS) Score

    EQ-5D VAS: participant rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline, thereafter every 3 cycles from Cycle 3 to Cycle 45 (each cycle = 21 days)

  10. Change From Baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire Score

    FACT-B questionnaire is used for assessment of health-related QoL in participants with breast cancer. It consists of 36 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (9 items) ranging from 0 to 36; high subscale score represents a better QoL. All single-item measures ranges from 0='Not at all' to 4='Very much'. Total possible score ranged from 0 to 144. High scale score represents a better QoL.

    Time frame: Baseline, thereafter every 3 cycles from Cycle 3 to Cycle 45 (each cycle = 21 days)

07

Results

Posted Nov 22, 2016

Participant flow

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Started106107
Completed7368
Not completed3339
Withdrew: Withdrawal by subject64
Withdrew: Lost to follow-up27
Withdrew: Death2223
Withdrew: Other35

Outcome measures

PrimaryPercentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Tumor response was assessed by investigator according to RECIST v1.1. BOR was defined as percentage of participants with a confirmed complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total or pathological nodes (with short axis \[SA\] of at least (\>/=) 15 millimeter \[mm\]) were identified as target lesions (TLs) and measured and recorded at baseline. A sum of diameters (longest for non-nodal lesions, SA for nodal lesions) for all TLs was calculated and reported as baseline sum of diameters (SD). All other lesions (or sites of disease) were identified as non-TLs. CR: disappearance of all TLs and SA reduction to less than (\<) 10 mm for nodal TLs/ non-TLs. PR: \>/=30 percent (%) decrease in SD of TLs, taking as reference baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. The 95% confidence interval (CI) was computed using Clopper-Pearson approach.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
percentage of participantsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)74.2 (63.8 to 82.9)63.7 (53.0 to 73.6)
SecondaryTime to Response as Assessed by Investigator According to RECIST v 1.1

For participants with a BOR of CR or PR, time to response = (Date of first confirmed CR/PR - Date of first study treatment) + 1. For participants without a CR or PR, time to response = (Date of adequate last tumor assessment - Date of first study treatment) + 1. For participant with no tumor assessment (or if all assessments were progressive disease \[PD\]) the censoring day was set to date of first study treatment +1. CR: the disappearance of all TLs and SA reduction to \<10 mm for nodal TLs/ non-TLs. PR: \>/=30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. The 95% CI was computed using log-log transformation.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Median · months
Time to Response as Assessed by Investigator According to RECIST v 1.1
monthsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Time to Response as Assessed by Investigator According to RECIST v 1.12.1 (2.0 to 2.2)2.2 (2.1 to 4.4)
SecondaryDuration of Response (DOR) as Assessed by Investigator According to RECIST v 1.1

DOR, in participants with a BOR of CR or PR, was defined as the period from the date of initial PR or CR until the date of PD or death from any cause. Participants with no documented PD or death after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively (regardless of the response at intermediate assessments). CR: the disappearance of all TLs and SA reduction to \<10 mm for nodal TLs/ non-TLs. PR: \>/=30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at 2 consecutive tumor assessments \>/=4 weeks apart was required. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. The 95% CI was computed using log-log transformation.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Median · months
Duration of Response (DOR) as Assessed by Investigator According to RECIST v 1.1
monthsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Duration of Response (DOR) as Assessed by Investigator According to RECIST v 1.113.3 (10.6 to 16.2)11.8 (7.5 to 17.9)
SecondaryPercentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1 or Death From Any Cause

PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Percentage of participants with radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or death due to any cause was reported.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1 or Death From Any Cause
percentage of participantsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1 or Death From Any Cause69.867.3
SecondaryProgression-free Survival (PFS) as Assessed by Investigator According to RECIST v 1.1

PFS was defined as the time from first intake of any study medication until the first radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or death due to any cause, whichever occurred first. Participants with no PFS events were censored at the time of the last evaluable tumor assessment. Participants with no baseline or no tumor assessment after the baseline visit were censored on the date of first study treatment. PD: \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Participants who had radio-graphically documented PD as assessed by investigator according to RECIST v1.1 or died due to any cause were considered as having an event. The median PFS was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Median · months
Progression-free Survival (PFS) as Assessed by Investigator According to RECIST v 1.1
monthsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Progression-free Survival (PFS) as Assessed by Investigator According to RECIST v 1.114.3 (11.2 to 17.5)11.5 (10.3 to 15.8)
SecondaryPercentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1

PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Percentage of participants with radio-graphically documented PD as assessed by investigator according to RECIST v1.1 was reported.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.1
percentage of participantsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Percentage of Participants With Disease Progression as Assessed by Investigator According to RECIST v1.167.961.7
SecondaryTime to Progression (TTP) as Assessed by Investigator According to RECIST v 1.1

TTP was defined as the time from first intake of any study medication until the first radio-graphically documented PD as assessed by investigator according to RECIST v1.1. Participants who did not have a radio-graphically documented PD and had died due to reason other than PD were censored on the last available tumor assessment prior to the death date. Participants with no baseline or no tumor assessment after the baseline visit were censored on the date of first study treatment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Participants who had radio-graphically documented PD as assessed by investigator according to RECIST v1.1 were considered as having an event. The median TTP was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

Time frame:
Baseline, every 3 cycles up to 36 months, and every 6 cycles thereafter if progression free after 36 months, 28 days after end of treatment, every 3 months thereafter (maximum up to approximately 3.5 years)
Reported as:
Median · months
Time to Progression (TTP) as Assessed by Investigator According to RECIST v 1.1
monthsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Time to Progression (TTP) as Assessed by Investigator According to RECIST v 1.114.9 (11.3 to 17.9)12.8 (10.4 to 17.1)
SecondaryPercentage of Participants Who Died From Any Cause

Percentage of participants who died due to any cause was reported.

Time frame:
Baseline until death (up to approximately 3.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died From Any Cause
percentage of participantsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Percentage of Participants Who Died From Any Cause21.721.5
SecondaryOverall Survival (OS)

OS was defined as the time from first intake of any study medication to the date of death, regardless of the cause of death. Participants who were known to be alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study treatment, and participants with no post-baseline information were censored at the date of first study treatment plus 1 day. Participants who died due to any cause were considered as having an event. The median OS was estimated using Kaplan-Meier method. The 95% CI was computed using log-log transformation.

Time frame:
Baseline until death (up to approximately 3.5 years)
Reported as:
Median · months
Overall Survival (OS)
monthsPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Visual Analogue Scale (VAS) Score

EQ-5D VAS: participant rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline, thereafter every 3 cycles from Cycle 3 to Cycle 45 (each cycle = 21 days)
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Visual Analogue Scale (VAS) Score
units on a scalePertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Baseline (n = 102, 102)69.7 ± 22.7468.6 ± 23.58
Change at Cycle 3 (n = 83, 90)0.9 ± 19.311.7 ± 23.16
Change at Cycle 6 (n=68, 82)1.0 ± 23.594.3 ± 24.49
Change at Cycle 9 (n=67, 68)2.2 ± 23.006.6 ± 26.29
Change at Cycle 12 (n=53, 59)-1.4 ± 30.196.8 ± 23.59
Change at Cycle 15 (n=43, 43)6.3 ± 19.348.1 ± 24.45
Change at Cycle 18 (n=32, 28)5.7 ± 21.836.5 ± 22.12
Change at Cycle 21 (n=30, 27)3.2 ± 20.001.3 ± 28.50
Change at Cycle 24 (n=25, 26)3.1 ± 17.062.8 ± 23.16
Change at Cycle 27 (n=21, 24)5.9 ± 18.791.1 ± 20.16
Change at Cycle 30 (n=18, 19)5.4 ± 19.879.5 ± 19.68
Change at Cycle 33 (n=15, 15)2.9 ± 24.0313.4 ± 19.65
Change at Cycle 36 (n=14, 7)4.8 ± 17.377.3 ± 21.72
Change at Cycle 39 (n=6, 1)15.8 ± 19.8550.0 ± NA
Change at Cycle 42 (n=2, 0)-5.0 ± 14.14NA ± NA
Change at Cycle 45 (n=1, 0)5.0 ± NANA ± NA
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire Score

FACT-B questionnaire is used for assessment of health-related QoL in participants with breast cancer. It consists of 36 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (9 items) ranging from 0 to 36; high subscale score represents a better QoL. All single-item measures ranges from 0='Not at all' to 4='Very much'. Total possible score ranged from 0 to 144. High scale score represents a better QoL.

Time frame:
Baseline, thereafter every 3 cycles from Cycle 3 to Cycle 45 (each cycle = 21 days)
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire Score
units on a scalePertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Baseline (n = 100, 100)76.7 ± 13.4678.5 ± 16.06
Change at Cycle 3 (n = 82, 90)-1.96 ± 10.872-2.57 ± 13.159
Change at Cycle 6 (n=70, 79)-0.97 ± 12.7490.47 ± 13.724
Change at Cycle 9 (n=65, 60)1.44 ± 13.189-0.42 ± 14.602
Change at Cycle 12 (n=52, 51)0.40 ± 12.0570.51 ± 14.510
Change at Cycle 15 (n=43, 44)2.72 ± 10.9890.09 ± 13.713
Change at Cycle 18 (n=32, 32)4.58 ± 11.8010.51 ± 16.512
Change at Cycle 21 (n=29, 24)3.22 ± 13.178-0.23 ± 16.116
Change at Cycle 24 (n= 26, 23)1.19 ± 10.660-1.03 ± 14.546
Change at Cycle 27 (n=20, 22)4.91 ± 9.9000.55 ± 14.185
Change at Cycle 30 (n=18, 24)3.96 ± 11.082-0.26 ± 17.381
Change at Cycle 33 (n=14, 17)5.75 ± 13.2721.76 ± 19.179
Change at Cycle 36 (n=15, 13)1.26 ± 9.2102.74 ± 14.354
Change at Cycle 39 (n=6, 6)-3.68 ± 16.8667.33 ± 20.992
Change at Cycle 42 (n=4, 0)-0.17 ± 10.599NA ± NA
Change at Cycle 45 (n=1, 0)1.00 ± NANA ± NA

Adverse events

Collected over Day 1 until 28 days after last study treatment (up to approximately 3.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion—32/106 (30.2%)103/106 (97.2%)
Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion—44/107 (41.1%)106/107 (99.1%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
Febrile neutropeniaBlood and lymphatic system disorders6/1063/107
PyrexiaGeneral disorders2/1066/107
HypersensitivityImmune system disorders5/1060/107
PneumoniaInfections and infestations2/1064/107
NeutropeniaBlood and lymphatic system disorders1/1063/107
Abdominal painGastrointestinal disorders2/1060/107
Drug hypersensitivityImmune system disorders2/1060/107
Septic shockInfections and infestations2/1061/107
Intestinal obstructionGastrointestinal disorders0/1062/107
NauseaGastrointestinal disorders0/1062/107
Most frequent other events
Showing 10 of 83
Most frequent other events
EventPertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single Infusion
DiarrhoeaGastrointestinal disorders61/10662/107
NeutropeniaBlood and lymphatic system disorders54/10661/107
NauseaGastrointestinal disorders52/10644/107
AstheniaGeneral disorders42/10629/107
FatigueGeneral disorders36/10641/107
AnaemiaBlood and lymphatic system disorders36/10619/107
ConstipationGastrointestinal disorders35/10635/107
PyrexiaGeneral disorders35/10622/107
VomitingGastrointestinal disorders34/10625/107
HypertensionVascular disorders8/10631/107

Baseline characteristics

Intent-to-treat (ITT) population included all participants enrolled into the study.

Age, Continuous
Age, Continuous(years)Pertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single InfusionTotal
Mean56.9 ± 11.8055.6 ± 13.1756.2 ± 12.50
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab + Vinorelbine: Separate InfusionPertuzumab + Trastuzumab + Vinorelbine: Single InfusionTotal
Female106106212
Male011
08

Study locations

80 sites
  • Tucson, Arizona 85724, United States
  • Stanford, California 94305-5151, United States
  • Denver, Colorado 80220, United States
  • Hollywood, Florida 33021, United States
  • Miami, Florida 33136, United States
  • Plantation, Florida 33324, United States
  • Marietta, Georgia 30060, United States
  • Boston, Massachusetts 02215, United States
  • Morristown, New Jersey 07960, United States
  • Durham, North Carolina 27710, United States
  • Columbus, Ohio 43210, United States
  • Houston, Texas 77090, United States
  • San Antonio, Texas 78229, United States
  • Ogden, Utah 84403, United States
  • Fredericksburg, Virginia 22408, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98195, United States
  • Rio de Janeiro, RJ 20560-120, Brazil
  • Barretos, SP 14784-400, Brazil
  • Sao Paulo, SP 01308-050, Brazil
  • Sao Paulo, SP 01317-000, Brazil
  • Sao Paulo, SP 04039-901, Brazil
  • Herlev, 2730, Denmark
  • Herning, 7400, Denmark
  • København Ø, 2100, Denmark
  • Odense, 5000, Denmark
  • Avignon, 84082, France
  • Bobigny, 93009, France
  • Caen, 14076, France
  • La Tronche, 38700, France
  • Mont-de-marsan, 40024, France
  • Paris, 75651, France
  • Paris, 75908, France
  • Perigueux, 24000, France
  • Pierre Benite, 69495, France
  • Plerin, 22190, France
  • Rouen, 76038, France
  • Strasbourg, 67065, France
  • Tours, 37044, France
  • Villejuif, 94805, France
  • Dortmund, 44263, Germany
  • Dresden, 01307, Germany
  • Frankfurt am Main, 60389, Germany
  • Freiburg, 79110, Germany
  • Georgsmarienhütte, 49124, Germany
  • Goslar, 38642, Germany
  • Gütersloh, 33332, Germany
  • Hamburg, 20357, Germany
  • Heidelberg, 69115, Germany
  • Kaiserslautern, 67655, Germany
  • Kassel, 34119, Germany
  • Köln, 50677, Germany
  • Lebach, 66822, Germany
  • Leer, 26789, Germany
  • Moers, 47441, Germany
  • München, 80335, Germany
  • München, 80639, Germany
  • Neumarkt, 92318, Germany
  • Ravensburg, 88212, Germany
  • Wuerselen, 52146, Germany
  • Bologna, Emilia-Romagna 40138, Italy
  • Aviano, Friuli-Venezia Giulia 33081, Italy
  • Roma, Lazio 00189, Italy
  • Genova, Liguria 16132, Italy
  • Cremona, Lombardia 26100, Italy
  • Monza, Lombardia 20900, Italy
  • Lido Di Camaiore, Toscana 55043, Italy
  • Pisa, Toscana 56100, Italy
  • Terni, Umbria 05100, Italy
  • Negrar, Veneto 37024, Italy
  • Oviedo, Asturias 33006, Spain
  • Terrassa, Barcelona 08227, Spain
  • Santander, Cantabria 39008, Spain
  • Barbastro, Huesca 22300, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • La Laguna, Tenerife 38320, Spain
  • Badajoz, 06080, Spain
  • Madrid, 28223, Spain
  • Malaga, 29010, Spain
  • Valencia, 46014, Spain
09

References and documents

Publications

  • Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Andersson M. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016 Dec 13;18(1):126. doi: 10.1186/s13058-016-0773-6. PubMed 27955684 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2012
First posted
Mar 28, 2012
Start
Apr 2012
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Nov 22, 2016
Last update
Nov 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01565083
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 28, 2012
Start date
Apr 2012
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Nov 22, 2016
Last update
Nov 22, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pertuzumab · Vinorelbine

Start the discussion